StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Medicines Co. (MDCO), Esperion Therapeutics (ESPR) Plunge Following Amgen's (AMGN) Repatha Data
March 17, 2017 9:04 AM
Medicines Co. (Nasdaq ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Momentum Movers
Trader Talk
Next Articles
Medicines Co. (MDCO), Alnylam (ALNY) Announces Positive Final Results from ORION-1 Phase II Study of Inclisiran
March 17, 2017 12:16 PM
Repatha Outcomes Data Reinforces Regeneron (REGN) Praluent Model - BTIG
March 17, 2017 11:52 AM
Medicines Co. (MDCO) Ticks Off Lows
March 17, 2017 11:42 AM
Amgen (AMGN) FOURIER Results 'Good Enough' - Cowen
March 17, 2017 11:23 AM
While Amgen (AMGN) Primary Endpoint Was Below Expectations, Secondary Endpoint was Encouraging - Goldman Sachs
March 17, 2017 11:05 AM
Amgen (AMGN) Says Outcomes Study Shows Repatha Decreases LDL-C to Unprecedented Low Levels, Reduces Risk of Cardiovascular Events
March 17, 2017 9:01 AM
Amgen (AMGN), Peers on Watch Ahead of Repetha Data at ACC.17 (REGN) (ESPR) (MDCO)
March 17, 2017 6:59 AM
